The primary wild-type organoids maintain native differentiation and 3D tissue architecture and allow mutant KRAS-targeting screening to be performed in well-defined human genetic backgrounds devoid of confounding mutations, which commonly occur in long-term passaging of 2D cancer cell lines. Here, KRAS is linked to cancer.